-
Prof. Hao Zeng: Key Takeaways from the West China Uro-Oncology Tianfu Conference and Advances in Precision Prostate Cancer Management
Editor’s Note: From November 10–16, 2025, the 9th West China Uro-Oncology Tianfu Academic Conference and the 11th Annual Meeting of the Genitourinary Tumor Committee of the Sichuan Anti-Cancer Association were…
-
Prof. Pei Dong: From “Effective” to “Precise” — Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
With the rapid progress of clinical research, immunotherapy has demonstrated substantial value across multiple treatment settings in renal cell carcinoma (RCC). In particular, immune-based combination regimens have reshaped the treatment landscape of advanced RCC. At the 9th West China Uro-Oncology Tianfu Academic Conference & the 11th Annual Meeting of the Sichuan Anti-Cancer Association Genitourinary Tumor Committee, Professor Pei Dong from Sun Yat-sen University…
-
West China UroOncology Tianfu Conference丨Professor Wei Xue Shares the Renji Experience in Comprehensive Prostate Cancer Management
01 Oncology Frontier – Urology Frontier: Your team was the first internationally to propose Raman spectroscopy–based noninvasive diagnosis using prostatic fluid. How do these innovations reshape the traditional diagnostic pathway…
-
Prof. Raynier Devillier: Three Key Focuses in HSCT for the Elderly—Disease Status, Conditioning Intensity, and Donor Selection
With the aging population, the demand for hematopoietic stem cell transplantation (HSCT) among elderly patients with hematologic malignancies is growing, yet clinical decision-making faces increasingly complex challenges. In the process…
-
Professor Alejandro Madrigal: The Path to Breakthrough for the Localization of CAR-T Cell Therapy in Latin America
In the global wave of medical innovation, emerging therapies such as CAR-T cell therapy have brought revolutionary hope for major diseases, including malignancies. However, their widespread adoption and application face significant regional imbalances, with low- and middle-income countries encountering numerous structural barriers in accessing these frontier technologies. From November 13 to 16, 2025, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, Zhejiang. During the conference, Oncology Frontier – Hematology specially invited Professor Alejandro Madrigal from University College London (UCL) to discuss, from an international perspective and using Mexico as a case study, the core challenges Latin America faces in promoting equitable access to medical resources and introducing cutting-edge therapies.
-
CCHIO 2025丨Guojun Zhang: A Landmark Event in Spring City Advancing Integrated Oncology Prevention and Treatment
01 Oncology Frontier: First of all, congratulations on the successful convening of CCHIO 2025 in Kunming. As the Executive Chair, could you introduce the core themes and major highlights of…
-
2025 CCHIO | Prof. Chen Xiaobing: Winning the Fight Against Cancer Through Integrated, Comprehensive Practice
Editor’s Note: In cancer prevention and treatment, integrative medicine is not merely a technical convergence but a human-centered medical philosophy. It breaks traditional disciplinary boundaries and weaves prevention, treatment, and…
-
2025 CCHIO | Prof. Li Hecheng: Advancing Early Lung Cancer Detection and Treatment Through Integrative and Multidisciplinary Strategies
Editor’s Note: From November 6–9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was held in Kunming. The conference was hosted by the Chinese Anti-Cancer Association (CACA)…
Connecting Medical Expertise through Media